Novavax (NASDAQ:NVAX) Stock Passes Above 200 Day Moving Average – Time to Sell?

Novavax, Inc. (NASDAQ:NVAX)’s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $7.92 and traded as high as $8.91. Novavax shares last traded at $8.70, with a volume of 3,215,968 shares traded.

Analyst Ratings Changes

A number of research firms have recently commented on NVAX. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 price target (down previously from $18.00) on shares of Novavax in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research report on Monday, December 29th. Cantor Fitzgerald began coverage on Novavax in a research note on Friday, October 24th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, January 20th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus target price of $11.25.

Novavax Stock Down 0.6%

The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 4.83 and a beta of 2.58. The firm’s fifty day moving average price is $7.86 and its two-hundred day moving average price is $7.93. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.27 and a quick ratio of 2.24.

Hedge Funds Weigh In On Novavax

A number of large investors have recently modified their holdings of NVAX. Flagship Harbor Advisors LLC bought a new stake in Novavax during the 4th quarter valued at $33,000. Quarry LP bought a new stake in shares of Novavax during the third quarter worth about $33,000. State of Wyoming bought a new stake in shares of Novavax during the second quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,617 shares during the last quarter. Finally, Danske Bank A S bought a new position in Novavax in the 3rd quarter valued at about $64,000. 53.04% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.